Clinical Trial Update: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating potential drug-drug interactions among IDX719, simeprevir, TMC647055, and ritonavir in healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IDX719 (NS5A inhibitor)
• Ritonavir (Norvir) (ritonavir)
• Simeprevir (Olysio) (simeprevir)
• TMC647055

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED